Company
Headquarters: Taizhou, China
Employees: 3,586
CN¥13.60 Billion
CNY as of July 1, 2025
US$1.90 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥5.18 B |
| EBITDA | CN¥1.01 B |
| Gross Profit TTM | CN¥1.64 B |
| Profit Margin | 11.97% |
| Operating Margin | 22.50% |
| Quarterly Revenue Growth | 1.00% |
Zhejiang Jiuzhou Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603456 wb_incandescent